Still expensive, but a solution is within reach
08/10/19 -"According the press, an out of court settlement for all Glyphosat-based cases seems now to be on Mr Baumann's agenda. Having lost the three original cases in the US, the idea of settling all of them ..."
Pages
64
Language
English
Published on
08/10/19
You may also be interested by these reports :
18/10/19
Roche’s Q3 19 sales growth of 13% CER is the highest quarterly growth in the last eight years. In oncology, the newer drugs have clearly taken over ...
17/10/19
Bulls have been in complete control of Faes Farma (Reduce, Spain) since the start of 2019. While solid Q4 18 results, fuelled by Bilastine (c.24% of ...
17/10/19
The acquisition of RA pharmaceuticals is expected to be margin-dilutive in the short/mid-term as UCB would be required to invest heavily in the ...
17/10/19
UCB has broadened its neuromuscular portfolio with the €2.2bn acquisition of RA pharmaceuticals – blockbuster potential drug, Zilucoplan (expected ...